Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Immunome revenue
Immunome's revenue is $9.0 million.
What is Immunome's revenue?
- Immunome's revenue growth from 2023 to 2024 is -35.5%.
- Immunome has 29 employees, and the revenue per employee ratio is $311,758.
- Immunome's peak quarterly revenue was $4.3M in 2023(q2).
- Immunome peak revenue was $14.0M in 2023.
- Immunome annual revenue for 2024 was 9.0M, -35.5% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Immunome financing
Immunome received early financing of $435.4K on 2009-09-11.
| Series | Round size | Date |
|---|---|---|
| Seed | $435K | 09/2009 |
| Series Unknown | $847K | 06/2011 |
| Seed | $145K | 01/2012 |
| Series Unknown | $445K | 02/2013 |
| Debt Financing | $735K | 03/2014 |
| Series Unknown | $468K | 10/2014 |
| Debt Financing | $200K | 02/2015 |
| Series A | $5M | 07/2016 |
| Series A | $7.2M | 10/2016 |
| Series Unknown | $9.3M | 11/2019 |
| Series A | $180K | 12/2019 |
| Series Unknown | $11M | 06/2020 |
| Post Ipo Equity | $13.3M | 07/2020 |
| Post Ipo Equity | $27M | 04/2021 |
| Grant | $17.6M | 07/2021 |
Immunome investors
| Investors | Security type |
|---|---|
| BioAdvance | Seed |
| BioAdvance | Series Unknown |
| BioAdvance | Seed |
| BioAdvance | Series Unknown |
| BioAdvance | Series Unknown |
| Robin Hood Ventures | Debt Financing |
| Evolution VC Partners | Series A |
| BioAdvance | Series A |
| Robin Hood Ventures | Series A |
| Robin Hood Ventures | Series Unknown |
| United States Department of Defense | Post Ipo Equity |
| JPEO-CBRND | Grant |
Search for jobs
Immunome highest paying jobs
Zippia gives an in-depth look into the details of Immunome, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Immunome. The employee data is based on information from people who have self-reported their past or current employments at Immunome. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Immunome. The data presented on this page does not represent the view of Immunome and its employees or that of Zippia.
Immunome may also be known as or be related to IMMUNOME INC., Immunome, Immunome Inc. and Immunome, Inc.